NOUSCOM ANNOUNCES THE PROMOTIONS OF LOREDANA SIANI TO VICE PRESIDENT OF TECHNICAL AND CMC DEVELOPMENT, TIFFANY BROOKE MULLER TO SENIOR VICE PRESIDENT OF FINANCE AND MORENA D’ALISE TO VICE PRESIDENT OF IMMUNOLOGY
We are glad to announce the following promotions of our team members: Loredana Siani to Vice President of Technical and CMC Development, Tiffany Brooke Muller to Senior Vice President of Finance and Morena D’Alise to Vice President of Immunology.
Loredana joined Nouscom as Technical Director in 2020, bringing a significant experience in process development and GMP production of viral vectored vaccines. She holds a PhD in Industrial Biotechnological Science from the University Federico II in Naples and an Executive MBA diploma from the Luiss Business School in Rome.
She is responsible for CMC development strategies of Nouscom’s product pipeline through the entire product development journey.
Tiffany joined Nouscom in 2019 as VP of Finance. She received her B.A. and M.A. in Mathematics and has 18 years of experience in finance including global treasury, FP&A, investments, and investor relations.
In her role, she manages the Finance and Procurement Logistics team and is responsible for providing leadership and financial oversight to develop and execute Nouscom’s strategic plans. She oversees financial operations including the planning, development, and implementation of the company’s budget, forecasts and day to day financial processes and is responsible for timely and accurate financial reporting in compliance with GAAP.
Morena joined Nouscom in 2016 as Senior group leader of the Immunology Department. She has more than 10 years’ experience in Immunology. She received her PhD in Biology and Molecular Biotechnology at the University of Perugia and then conducted her post-doctoral studies in Immunology at Harvard Medical School focusing on mechanism of Immunoregulation where she built strong expertise on the characterization of immune response in preclinical animal models and in human samples.
In her role, she leads the Immunology team with focus on characterization of vaccine immunogenicity and mechanism of action in preclinical and clinical settings, drives company interactions with external collaborators for the evaluation of genetic vaccine platforms in tumor models and liaises with internal teams to design immunogenicity evaluation strategies.